In this review, we discuss known data and the differences between the different immune checkpoint inhibitors, as well as future avenues to explore with immuno-oncologic agents in urothelial cancer.
Emily A. Lemke, DNP, AGPCNP-BC, AOCNP
Advertisement
Articles by Emily A. Lemke, DNP, AGPCNP-BC, AOCNP
Advertisement
Latest Updated Articles
Current and Future Landscape of Immune Checkpoint Inhibitors in Urothelial CancerPublished: January 17th 2019 | Updated:
Advertisement
Advertisement
Trending on CancerNetwork
1
AI-Powered Scout Platform Could Enhance Oncology Decision-Making With Data- and Expert-Driven Insights
2
Molecular Insights Into Cancer Cachexia: An Evolution in Identifying the Syndrome
3
FDA Grants Interchangeability Designation to 2 Denosumab Biosimilars
4
Sac-TMT Combo Produces Encouraging Activity in Pretreated Metastatic CRPC
5
